Movement Alert｜GENFLEET-B Falls 5.49% in Regular Trading, Competitor RAS Inhibitor NDA Accepted by FDA Continues to Pressure Pipeline

Market Focus07-29

On July 29, GENFLEET-B fell 5.49% in regular trading, trading at 27.08 HKD/share with turnover of 16.95 million HKD, extending the previous session's decline.

On the news front, competitor Revolution Medicines' oral RAS inhibitor daraxonrasib has had its NDA accepted by the FDA, based on data from the pivotal Phase III RASolute 302 study. GENFLEET-B's core product GFH375 is also a KRAS G12D inhibitor currently conducting a Phase III registrational study in second-line and beyond pancreatic cancer. The competitor's advancement into regulatory review ahead of GENFLEET-B poses sustained pressure on the company's best-in-class positioning. Additionally, institutional holder Wellington Management recently made a small reduction in its stake, contributing to weak market sentiment around the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139222405?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139222405","market":"hk","top_or_hot":-1,"title":"Movement Alert｜GENFLEET-B Falls 5.49% in Regular Trading, Competitor RAS Inhibitor NDA Accepted by FDA Continues to Pressure Pipeline","media":"Market Focus","content":"<p><p>On July 29, GENFLEET-B fell 5.49% in regular trading, trading at 27.08 HKD/share with turnover of 16.95 million HKD, extending the previous session's decline.</p><p>On the news front, competitor Revolution Medicines' oral RAS inhibitor daraxonrasib has had its NDA accepted by the FDA, based on data from the pivotal Phase III RASolute 302 study. GENFLEET-B's core product GFH375 is also a KRAS G12D inhibitor currently conducting a Phase III registrational study in second-line and beyond pancreatic cancer. The competitor's advancement into regulatory review ahead of GENFLEET-B poses sustained pressure on the company's best-in-class positioning. Additionally, institutional holder Wellington Management recently made a small reduction in its stake, contributing to weak market sentiment around the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GENFLEET-B Falls 5.49% in Regular Trading, Competitor RAS Inhibitor NDA Accepted by FDA Continues to Pressure Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GENFLEET-B Falls 5.49% in Regular Trading, Competitor RAS Inhibitor NDA Accepted by FDA Continues to Pressure Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-29 10:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 29, GENFLEET-B fell 5.49% in regular trading, trading at 27.08 HKD/share with turnover of 16.95 million HKD, extending the previous session's decline.</p><p>On the news front, competitor Revolution Medicines' oral RAS inhibitor daraxonrasib has had its NDA accepted by the FDA, based on data from the pivotal Phase III RASolute 302 study. GENFLEET-B's core product GFH375 is also a KRAS G12D inhibitor currently conducting a Phase III registrational study in second-line and beyond pancreatic cancer. The competitor's advancement into regulatory review ahead of GENFLEET-B poses sustained pressure on the company's best-in-class positioning. Additionally, institutional holder Wellington Management recently made a small reduction in its stake, contributing to weak market sentiment around the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02595","symbol_name":"劲方医药-B","start_time":0,"source_url":"","article_id":"1139222405","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139222405","pubTimestamp":1785290416,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 29, GENFLEET-B fell 5.49% in regular trading, trading at 27.08 HKD/share with turnover of 16.95 million HKD, extending the previous session's decline.On the news front, competitor Revolution...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02595":"劲方医药-B"},"translate_title":"走势警报|GENFLEET-B常规交易跌5.49%，竞争对手RAS抑制剂NDA获FDA受理继续给管道施压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02595":1},"content_text":"On July 29, GENFLEET-B fell 5.49% in regular trading, trading at 27.08 HKD/share with turnover of 16.95 million HKD, extending the previous session's decline.On the news front, competitor Revolution Medicines' oral RAS inhibitor daraxonrasib has had its NDA accepted by the FDA, based on data from the pivotal Phase III RASolute 302 study. GENFLEET-B's core product GFH375 is also a KRAS G12D inhibitor currently conducting a Phase III registrational study in second-line and beyond pancreatic cancer. The competitor's advancement into regulatory review ahead of GENFLEET-B poses sustained pressure on the company's best-in-class positioning. Additionally, institutional holder Wellington Management recently made a small reduction in its stake, contributing to weak market sentiment around the stock.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139222405","isCrawlerRequest":true}